Introduction
Non-adherence to medications is considered as one of the largest drug related issues. WHO states that non-adherence to medications is a "worldwide problem of striking magnitude." 1 Poor medication adherence can cause negative health outcomes such as worsening disease or even death and studies showed that there was an association between poor adherences to medications indicated for chronic diseases with health resources utilization. 2 Poor medication adherence also may result in increased health care cost.
There are 33%-69% of drug-related hospital admissions in US are because of poor medication adherence, along with a cost of about $100 billion a year. 3 So far there is no gold standard method to measure medication taking behavior. Methods of measuring adherence can be classified as direct method and indirect method. Direct methods include directly observed therapy, measurement of drug concentration in blood, and measurement of the biologic marker in the body. Indirect methods include patient self-report, pill counts, pharmacy fill data, electronic medication monitoring, and assessment of patient's clinical response. 3 Patient self-report or questionnaire is one of the important indirect methods of measuring medication adherence and persistence and it's the most commonly used method in the clinical setting. Although it's simple and easy, studies show it can measure medication adherence effectively 4, 5 and has moderate to high degree of concordance with electronic medication monitoring device. 6 The problems with patient self-report involve with the distortion of results by patients themselves, misinterpretation of the information in the instrument or potential error increasing in time between visits.
In 1986, Dr. 9 It was found that the with-in person change of as or more than 2 scores of MMAS-8 indicated a real change of medication adherence in the hypertensive population. 10 Nevertheless, The measurement of adherence by the Morisky scale and its modification still cannot be quantified very well 9 and this might limit their application.
Medication adherence scales are a subjective measure of medication adherence, used for studies conducted in different patient populations with various disease conditions. Many of the adherence scales are validated and compared against an objective measure of medication adherence. A medication adherence scale should be able to accurately capture the beliefs, barriers and behavior related to medication adherence. It should also be easy to administer, understand and be precise. 11 Given the strengths and weaknesses of MMAS-4 and MMAS-8, we think it necessary to investigate how they are used in the clinical studies, their psychometric properties reported in the studies, issues with the use, and also find out what are the future directions to improve the development and implementation of these selfreported instruments in measuring medication adherence. This study also briefly reviews other popular medication adherence scales available for measuring medication adherence. Table 1 attached below listed the studies since 2008 using MMAS-4 and MMAS-8 as adherence measurement. 2, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] From the literature review, we have found that Morisky scale and its derivate have moderate to high reliability and criterion validity in some studies, yet there is still some space of improving translational validity including face validity or content validity. Of significance, clinicians or researchers should be cautious before using them as medication measurements and need to think about two key points: 1) whether MMAS is appropriate to be used in order to reach the goal of the study or an intervention; 2) if MMAS is validated in this specific situation which may be distinct from the original setting of validation.
Current use of MMAS-4 and MMAS-8 to measure medication adherence
MMAS-4 and MMAS-8 are designed to describe the medication taking behavior of patients but they seem not to be able to comprehensively assess the reasons or predictors of medication adherence. They can be regards as good estimates of the medication taking behavior, yet not good explanatory tools of figuring out why patients are not adherent, which may lead to poor relationship between the Morisky scale and objective clinical outcome measures. For instance, study of medication adherence in Thailand diabetic population found that blood glucose levels were not associated with Morisky scale scores. 18 In addition, they are good screening and monitoring tools to identify those patients who might have medication adherence problems. However, if health care providers would like to develop some strategies or interventions to improve the adherence, these instruments cannot provide adequate informative support since they are lack of data or information regarding the reasons or predictors of medication adherence.
It is important to test the psychometric properties in a specific situation before choosing the instrument to measure medication adherence. Nina van de Steeg et al. showed that MMAS-4 was not valid for patients taking antihypertensive medications in Germany. 16 Although not many similar results have been found (probably due to publication bias), these studies can still be regarded as red flags to emphasize the importance and necessity to validate MMAS in such situations distinct from the original setting of validation before using MMAS as medication measurement. Face validity is to determine whether the measurement of the overall instrument and its items congruent with the underlying construct, and it is usually based on personal judgment. 23 Although it is a qualitative and subjective assessment of the instrument, it is good to be used to refine or evaluate the instrument. With the increasing applications of Morisky scale and advances in medication adherence research, we are equipped with more theoretical knowledge, empirical evidence, and a broader range of perspectives to help us to further refine and evaluate the wording, phrasing, and construct. In terms of content validity, there are two dimensions in MMAS-4 if we consider whether the nonadherence is intentional or unintentional. The first two items are assessing the unintentional non-adherence due to forgetfulness and carelessness. The last two items are measuring the intentional non-adherence ---stopping medications when feeling better or worse. 10 In the studies developing MMAS-4 and MMAS-8, psychometric properties were tested in the hypertensive population and found that all items were unidimensional. 8, 9 However, another study testing the psychometric properties of MMAS-8 in diabetic patients in Thailand found that MMAS-8 had three dimensions including forgetting to take medications, stopping medications when feeling better or worse, and the complexity of the drug regimen. 18 Given the existing inconsistency in content validity, further research on testing the content validity in different disease and population using robust study design and methods are warranted.
Other medication adherence scales
Beliefs about Medicines Questionnaires (BMQ): There are 2 sections of Beliefs about Medicines Questionnaires (BMQ): a two 4 item factor BMQ-General section and a two 5 item factor BMQ-Specific section. BMQ-Specific looks at beliefs associated with medications that the patient is on whereas BMQ-General looks at beliefs associated with medications in general. The two factors of BMQ-General section assess the beliefs associated with harm caused by medications (GeneralHarm) and the overuse of medications (General-Overuse).
The two factors of BMQ-Specific section assess the beliefs associated with the need to take medications (SpecificNecessity) and the long term effects of medications (SpecificConcerns). When the scale was first developed, it was used by patients admitted in departments such as asthma, diabetes, renal disease, cardiac disorders, psychiatric disorders and general medicine. Overall, the four factors of the BMQ scale showed good to acceptable internal consistencies. In case of BMQ-General harm factor, the internal consistency was quite low for asthma (0.47), cardiac (0.51) and general medicine (0.51) patients respectively. 23, 24 The BMQ scale has displayed satisfactory validity and reliability when used in patients residing in different countries and for different disease conditions. 25, 26 However, when the BMQ-Specific scale was translated to Scandinavian languages such as Norwegian, Swedish and Danish; the content validity was found to be weak. The meanings of certain questions were unclear or totally different after translation. Also, the endpoints of the Likert scale extended at one end-point for the Swedish version and at both endpoints for the Danish version. 27 In another study, when the BMQ-General scale was translated in Spanish language and administered to psychiatric outpatients, medical students, and psychology students to study the medication beliefs associated with psychiatric medications, medium low internal consistency was found. Also, when the 3 population samples were analyzed separately, the BMQ-General scale identified 3 different structures for each of the two factors. 28 The Medication Adherence Rating Scale (MARS): The Medication Adherence Rating Scale (MARS) is a measure of medication adherence developed from Medication Adherence Questionnaire and Drug Attitude Inventory. 29 MARS consists of 10 items represented by 3 factors: medication adherence behavior, attitude towards medication and general illness control. 30 MARS was first administered in psychosis patients. The reliability of MARS is adequate and validity is moderate. The internal consistency of MARS has been shown to vary from moderate to very good. Some of the format related reasons for this might be the binary response choice, less items and scale multidimensionality. 30, 31 The medication adherence behavior factor correlates better with medication adherence compared to attitude towards medication factor. In larger samples, the attitude towards medication factor is not a very good predictor of medication adherence. 30, 31 One of the advantages of using MARS is that the scale takes in account patient behavior of not regularly taking medications by not considering them non-compliant. 31 Adherence Self-Report Questionnaire (ASRQ): Adherence Self-Report Questionnaire (ASRQ) was developed by de Klerk and colleagues and comprises of six different levels of adherence ranging from 'perfect' (level 1) to 'low' (level 6). 32 Generally, ASRQ is administered with medication event monitoring systems (MEMS) cap to measure timing adherence or correct dosing or adherence related to intake of doses. ASRQ is not an optimal tool to measure medication non adherence or poor medication adherence due to low sensitivity or low positive predictive values. ASRQ has been used to monitor anti-hypertensive medication adherence. is the ASK-12 which has adequate reliability and validity as well. 36 Hill-Bone compliance scale: Hill-Bone compliance scale primarily focuses on hypertension medication adherence. This scale has 3 sub-scales: reduced sodium intake, appointment timeliness and medication intake. It has a four point Likert scale rating and a very good internal consistency. 37 However; this scale can be used only in hypertension patients so it has limited generalizability. This scale has also demonstrated high internal consistency when used in South Africa 38 or when translated to Turkish. 39 However, when the scale was used in Germany, it showed floor effects and poor ability to predict medication adherence for nearly every third participant. The researchers indicated the need to rethink about the theoretical framework upon which the scale was designed.
Recommendations for future development and research
Based on the review of the development and implementations of Morisky scale and its modification, we believe there is still some space for us to improve these instruments.
First, it is essential to further improve its face validity and content validity to ensure great construct validity. As discussed above, we could integrate more theoretical knowledge, empirical evidence, and different perspectives to further refine and evaluate the wording, phrasing, construct and etc. To achieve a comprehensive assessment of medication adherence, we may add some items addressing more reasons or predictors of non-adherence such as disease and medication knowledge, physician patient communication, treatment satisfaction and medication belief. We can also include more use of other measurement scales such as Likert scale and visual analog scale. In this way, we could enhance the internal consistency reliability by increasing the response choices and lowering the measurement errors. 23 Content validity needs to be tested in different situations to ensure the items and the overall instrument reflect the dimensions of the construct.
Second, although adherence measurements are often reported as dichotomous variables (adherence vs. nonadherence), adherence can actually vary from 0% to over 100%, since patients take more than the prescribed amount of drugs in certain cases. 3 Currently most medication adherence instruments including Morisky scale mainly focus on assessing the medication underuse part, yet the other side of medication non-adherence --overuse of medications seems to be neglect in the development of these instruments. As the medication overuse issue continues to grow in the United States and attracts more and more attentions, we believe there is an increasing need to take into account the medication overuse issue in developing a general medication use instrument.
Third, patients with multiple comorbidities may hold diverse medication beliefs and medication taking behaviors for different diseases and medications. In other word, patients may be adherent to certain medications but not others. Yet the items of Morisky scale are designed for patients to solely focus on one specific disease state at one time. Future attempt may need to think of this problem from a wholeperson care perspective.
Overall, MMAS-4 and MMAS-8 are good screening and monitoring tools in clinical practice to identify and monitor the high-risk non-adherent patients. Further studies of patient-reported instruments are warranted to better assess medication taking behaviors and validate them in different populations and settings. 
